SALES HISTORY – SINCE IPO



2019-20 in summary

- 15 years as a public company
- Acquisition of Tristel Italia
- Launch of Cache surface portfolio
- Impact of Covid-19
- 21% y-o-y sales growth in 2020
- 17% CAGR since IPO



SALES HISTORY – BY GEOGRAPHY



2019-20 in summary

- UK sales growth 7%
- International sales growth 32%
- International sales benefit from Tristel Italia contribution – acquired July 19
- International sales now represent 60% of all revenue



SALES HISTORY – BY PRODUCT CATEGORY



2019-20 in summary

- 12% Tristel medical device sales growth
- 139% Cache surface sales growth

Estimated Covid-19 impact

- £500k reduction in Tristel medical device sales
- £2m increase in Cache surface sales



SECOND HALF SALES – COVID IMPACT



- March: Hospitals build their stock of all infection prevention products.
- April: Out-patient departments close to all but Covid-19 patients. Reduced Tristel sales, but Cache sales hit an all time high.
- May: Australasia, Asia & Europe outpatient departments prepare to re-open.
- June: UK out-patient departments prepare to re-open.





COVID IMPACT - PRODUCTION

Bulk Solution Manufacture 2019-20



February & March 2020

• Senior management team prepares a Covid-19 response plan

April & May 2020

- 100% increase in bulk solution manufacture
- 100% increase in out-sourced sachet filling output
- 100% increase in production personnel
- The implementation of a fast response plan allowed demand to be met.

